Lisa S. Blatt, Washington, DC, for petitioners. Ginger D. Anders, for United States, as amicus curiae, by special leave of the Court, supporting the petitioners. David C. Frederick, Washington, DC, for the respondent. Miguel Marquez, County Counsel, Greta S. Hansen, Juniper L. Downs, James R. Williams, Office of the County Counsel, County of Santa Clara, San Jose, California, Sanford Svetcov, Jeffrey W. Lawrence, Susan K. Alexander, Aelish M. Baig, Robbins Geller Rudman & Dowd LLP, San Francisco, California, David C. Frederick, Counsel of Record, Scott H. Angstreich, Scott K. Attaway, Kellogg, Huber, Hansen, Todd, Evans & Figel, P.L.L.C., Washington, D.C., for respondent. Lisa S. Blatt, Counsel of Record, Jeffrey L. Handwerker, Anthony J. Franze, Kristin M. Hicks, Arnold & Porter LLP, Washington, DC, for Petitioners Astra USA, Inc., AstraZeneca Pharmaceuticals LP and Zeneca Inc. James P. Muehlberger, Robert J. McCully, Ina D. Chang, Shook, Hardy & Bacon LLP, Kansas City, MO, for Petitioners Aventis Pharmaceuticals Inc. and ZLB Behring LLC. Paul J. Riehle, Matthew A. Fischer, Sedgwick, Detert, Moran & Arnold LLP, San Francisco, CA, Lyndon M. Tretter, Jessica P. Feingold, Hogan Lovells US LLP, New York, NY, for Petitioner Bristol-Myers Squibb Company. Richard D. Raskin, Scott D. Stein, Sidley Austin LLP, Chicago, IL, for Petitioner Bayer Corporation. Kirke M. Hasson, Colin T. Kemp, Pillsbury Winthrop Shaw Pittman LLP, San Francisco, CA, for Petitioner Merck & Co., Inc. f/d/b/a/ Schering-Plough Corporation. Frederick G. Herold, Dechert LLP, Mountain View, CA, for Petitioner SmithKline Beecham Corporation d/b/a GlaxoSmithKline. Brian W. Shaffer, Erica Smith-Klocek, Jennifer Jordan, Morgan, Lewis & Bockius LLP, Philadelphia, PA, R. Ted Cruz, Allyson N. Ho, Morgan, Lewis & Bockius LLP, Houston, TX, for Petitioner Pfizer Inc. Peter N. Larson, David L. Wallach, Jones Day, San Francisco, CA, for Petitioners Tap Pharmaceutical Products Inc. n/k/a Takeda Pharmaceuticals North America, Inc. Fletcher C. Alford, Ryan B. Polk, Gordon & Rees LLP, San Francisco, CA, S. Craig Holden, Kelly J. Davidson, Ober Kaler, Grimes & Shriver, Baltimore, MD, for Petitioners Wyeth, Inc. and Wyeth Pharmaceuticals, Inc.
Lisa S. Blatt, Washington, DC, for petitioners.
Ginger D. Anders, for United States, as amicus curiae, by special leave of the Court, supporting the petitioners.
David C. Frederick, Washington, DC, for the respondent.
Miguel Marquez, County Counsel, Greta S. Hansen, Juniper L. Downs, James R. Williams, Office of the County Counsel, County of Santa Clara, San Jose, California, Sanford Svetcov, Jeffrey W. Lawrence, Susan K. Alexander, Aelish M. Baig, Robbins Geller Rudman & Dowd LLP, San Francisco, California, David C. Frederick, Counsel of Record, Scott H. Angstreich, Scott K. Attaway, Kellogg, Huber, Hansen, Todd, Evans & Figel, P.L.L.C., Washington, D.C., for respondent.
Lisa S. Blatt, Counsel of Record, Jeffrey L. Handwerker, Anthony J. Franze, Kristin M. Hicks, Arnold & Porter LLP, Washington, DC, for Petitioners Astra USA, Inc., AstraZeneca Pharmaceuticals LP and Zeneca Inc.
James P. Muehlberger, Robert J. McCully, Ina D. Chang, Shook, Hardy & Bacon LLP, Kansas City, MO, for Petitioners Aventis Pharmaceuticals Inc. and ZLB Behring LLC. Paul J. Riehle, Matthew A. Fischer, Sedgwick, Detert, Moran & Arnold LLP, San Francisco, CA, Lyndon M. Tretter, Jessica P. Feingold, Hogan Lovells US LLP, New York, NY, for Petitioner Bristol-Myers Squibb Company.
Richard D. Raskin, Scott D. Stein, Sidley Austin LLP, Chicago, IL, for Petitioner Bayer Corporation.
Kirke M. Hasson, Colin T. Kemp, Pillsbury Winthrop Shaw Pittman LLP, San Francisco, CA, for Petitioner Merck & Co., Inc. f/d/b/a/ Schering-Plough Corporation. Frederick G. Herold, Dechert LLP, Mountain View, CA, for Petitioner SmithKline Beecham Corporation d/b/a GlaxoSmithKline.Brian W. Shaffer, Erica Smith-Klocek, Jennifer Jordan, Morgan, Lewis & Bockius LLP, Philadelphia, PA, R. Ted Cruz, Allyson N. Ho, Morgan, Lewis & Bockius LLP, Houston, TX, for Petitioner Pfizer Inc.
Peter N. Larson, David L. Wallach, Jones Day, San Francisco, CA, for Petitioners Tap Pharmaceutical Products Inc. n/k/a Takeda Pharmaceuticals North America, Inc.
Fletcher C. Alford, Ryan B. Polk, Gordon & Rees LLP, San Francisco, CA, S. Craig Holden, Kelly J. Davidson, Ober Kaler, Grimes & Shriver, Baltimore, MD, for Petitioners Wyeth, Inc. and Wyeth Pharmaceuticals, Inc.
Justice GINSBURG, Delivered the opinion of the Court.Section 340B of the Public Health Services Act, 42 U.S.C.A. § 256b (Oct.2010 Supp.), imposes ceilings on prices drug manufacturers may charge for medications sold to specified health care facilities. Those facilities, here called "340B" or "covered" entities, include public hospitals and community health centers, many of them providers of safety-net services to the poor. The § 340B ceiling-price program (340B Program) is superintended by the Health Resources and Services Administration (HRSA), a unit of the Department of Health and Human Services (HHS). Drug manufacturers opt into the 340B Program by signing a form Pharmaceutical Pricing Agreement (PPA) used nationwide. PPAs are not transactional, bargained-for contracts. They are uniform agreements that recite the responsibilities § 340B imposes, respectively, on drug manufacturers and the Secretary of HHS. Manufacturers' eligibility to participate in State Medicaid programs is conditioned on their entry into PPAs for covered drugs purchased by 340B entities.
It is conceded that Congress authorized no private right of action under § 340B for covered entities who claim they have been charged prices exceeding the statutory ceiling. This case presents the question whether 340B entities, though accorded no right to sue for overcharges under the statute itself, may nonetheless sue allegedly overcharging manufacturers as third-party beneficiaries of the PPAs to which the manufacturers subscribed. We hold that suits by 340B entities to enforce ceiling-price contracts running between drug manufacturers and the Secretary of HHS are incompatible with the statutory regime.Congress placed the Secretary (acting through her designate, HRSA) in control of § 340B's drug-price prescriptions. That control could not be maintained were potentially thousands of covered entities permitted to bring suits alleging errors in manufacturers' price calculations. If 340B entities may not sue under the statute, it would make scant sense to allow them to sue on a form contract implementing the statute, setting out terms identical to those contained in the statute. Though labeled differently, suits to enforce § 340B and suits to enforce PPAs are in substance one and the same. Their treatment, therefore, must be the same, "[n]o matter the clothing in which [340B entities] dress their claims." Tenet v. Doe, 544 U.S. 1, 8, 125 S.Ct. 1230, 161 L.Ed.2d 82 (2005).
The 340B Program is tied to the earlier-enacted, much larger Medicaid Drug Rebate Program. Adopted by Congress in 1990, the Medicaid Rebate Program covers a significant portion of drug purchases in the United States. See GAO, J. Dicken, Prescription Drugs: Oversight of Drug Pricing in Federal Programs 1 (GAO–07–481T, 2007) (testimony before the Committee on Oversight and Government Reform, House of Representatives). To gain payment under Medicaid for covered drugs, a manufacturer must enter a standardized agreement with HHS; in the agreement, the manufacturer undertakes to provide rebates to States on their Medicaid drug purchases. 104 Stat. 1388–143, as amended, 124 Stat. 3290, 42 U.S.C.A. § 1396r–8(a). The amount of the rebates depends on the manufacturer's "average" and "best" prices, as defined by legislation and regulation. § 1396r–8(c), (k).
"In 2004, Medicaid ... prescription drug spending reached $31 billion," GAO, J. Dicken, Prescription Drugs: Oversight of Drug Pricing in Federal Programs 4 (GAO–07–481T, 2007) (testimony before the Committee on Oversight and Government Reform, House of Representatives), while in 2003, 340B entities "spent an estimated $3.4 billion on drugs," id., at 5.
Calculation of a manufacturer's "average" and "best" prices, undertaken by the pharmaceutical company, is a complex enterprise requiring recourse to detailed information about the company's sales and pricing. § 1396r–8(k) ; 42 CFR § 447.500 – 520 (2010). To enable HHS to calculate the rebate rate for each drug, manufacturers submit the relevant data to HHS on a quarterly basis. § 1396r–8(b)(3). With exceptions set out in the legislation, HHS is prohibited from disclosing the submitted information "in a form which discloses the identity of a specific manufacturer ... [or] prices charged for drugs by such manufacturer." § 1396r–8(b)(3)(D).
Under § 340B, added in 1992, 106 Stat. 4967, as amended, 124 Stat. 823, manufacturers participating in Medicaid must offer discounted drugs to covered entities, dominantly, local facilities that provide medical care for the poor. See § 256b(a) ; § 1396r–8(a)(1). The 340B Program, like the Medicaid Drug Rebate Program, employs a form contract as an opt-in mechanism. The 340B Program also draws on the larger scheme's pricing methodology. In their 340B Program contracts with HHS, called Pharmaceutical Pricing Agreements (PPAs), see supra, at 1345, manufacturers agree to charge covered entities no more than predetermined ceiling prices, derived from the "average" and "best" prices and rebates calculated under the Medicaid Drug Rebate Program. § 256b(a)(1) ; see App. to Pet. for Cert. 165a–171a (PPA § I–II).
The 340B Program also covers over-the-counter medications for which there are no Medicaid rebates. 42 U.S.C.A. § 256b(a)(2)(B) (Oct.2010 Supp.). For such drugs, § 340B prescribes a substitute calculation method. § 256b(a)(2)(B)(i).
If a manufacturer overcharges a covered entity, HRSA may require the manufacturer to reimburse the covered entity; HRSA may also terminate the manufacturer's PPA, § 1396r–8(b)(4)(B)(i), (v) ; App. to Pet. for Cert. 174a (PPA § IV(c)), which terminates as well the manufacturer's eligibility for Medicaid coverage of its drugs, § 1396r–8(a)(1), (5). Currently, HRSA handles overcharge complaints through informal procedures. Manufacturer Audit Guidelines and Dispute Resolution Process, 61 Fed.Reg. 65412 (1996). The 2010 Patient Protection and Affordable Care Act (PPACA), Pub.L. 111–148, 124 Stat. 119, provides for more rigorous enforcement. The PPACA directs the Secretary to develop formal procedures for resolving overcharge claims. Id ., at 826, 42 U.S.C.A. § 256b(d)(3)(A). Under those procedures, which are not yet in place, HRSA will reach an "administrative resolution" that is subject to judicial review under the Administrative Procedure Act (APA), 5 U.S.C. § 701 et seq . See 124 Stat. 827, 42 U.S.C.A. § 256b(d)(3)(C). In addition to authorizing compensation awards to overcharged entities, the PPACA provides for the imposition of monetary penalties payable to the Government. Id ., at 824–825, 42 U.S.C.A. § 256b(d)(1)(B)(ii), (vi).
Respondent Santa Clara County (County), operator of several 340B entities, commenced suit against Astra and eight other pharmaceutical companies, alleging that the companies were overcharging 340B health care facilities in violation of the PPAs to which the companies subscribed. The County styled its suit a class action on behalf of both 340B entities in California and the counties that fund those entities. Asserting that the 340B entities and the counties that fund them are the intended beneficiaries of the PPAs, the County sought compensatory damages for the pharmaceutical companies' breach of contract.
The District Court dismissed the complaint, concluding that the PPAs conferred no enforceable rights on 340B entities. Reversing the District Court's judgment, the Ninth Circuit held that covered entities, although they have no right to sue under the statute, could maintain the action as third-party beneficiaries of the PPAs. 588 F.3d 1237, 1241 (2009).
U.S. Courts of Appeals have divided on the circumstances under which suits may be brought by alleged third-party beneficiaries of Government contracts. Compare 588 F.3d 1237, 1244 (C.A.9 2009) (case below) ("Any intended beneficiary has the right to enforce the obligor's duty of performance ... ."), with Grochowski v. Phoenix Construction, 318 F.3d 80, 85–86 (C.A.2 2003) ("there is no presumption in favor of a right to bring suit" as third-party beneficiary of a government contract), and Dewakuku v. Martinez, 271 F.3d 1031, 1042 (C.A.Fed.2001) (rejecting third-party suit).
As the County conceded below and before this Court, see 588 F.3d, at 1249 ; Tr. of Oral Arg. 45, covered entities have no right of action under § 340B itself. "[R]ecognition of any private right of action for violating a federal statute," currently governing decisions instruct, "must ultimately rest on congressional intent to provide a private remedy." Virginia Bankshares, Inc. v. Sandberg, 501 U.S. 1083, 1102, 111 S.Ct. 2749, 115 L.Ed.2d 929 (1991). See also Stoneridge Investment Partners, LLC v. Scientific–Atlanta, Inc., 552 U.S. 148, 164, 128 S.Ct. 761, 169 L.Ed.2d 627 (2008) ; Alexander v. Sandoval, 532 U.S. 275, 286, 121 S.Ct. 1511, 149 L.Ed.2d 517 (2001). Congress vested authority to oversee compliance with the 340B Program in HHS and assigned no auxiliary enforcement role to covered entities.
Notwithstanding its inability to assert a statutory right of action, the County maintains that the PPAs implementing the 340B Program are agreements enforceable by covered entities as third-party beneficiaries. A nonparty becomes legally entitled to a benefit promised in a contract, the County recognizes, only if the contracting parties so intend. Brief for Respondent 31 (citing Restatement (Second) of Contracts § 302(1)(b) (1979) ). The PPAs "specifically nam[e]" covered entities as the recipients of discounted drugs, the County observes; indeed the very object of the agreements is to ensure that those entities would be "charge[d] ... no more than the ceiling price." Brief for Respondent 33. When the Government uses a contract to secure a benefit, the County urges, the intended recipient acquires a right to the benefit enforceable under federal common law. Id ., at 30. But see 9 J. Murray, Corbin on Contracts § 45.6, p. 92 (rev. ed. 2007) ("The distinction between an intention to benefit a third party and an intention that the third party should have the right to enforce that intention is emphasized where the promisee is a governmental entity.").
The County's argument overlooks that the PPAs simply incorporate statutory obligations and record the manufacturers' agreement to abide by them. The form agreements, composed by HHS, contain no negotiable terms. Like the Medicaid Drug Rebate Program agreements, see supra, at 1346, the 340B Program agreements serve as the means by which drug manufacturers opt into the statutory scheme. A third-party suit to enforce an HHS-drug manufacturer agreement, therefore, is in essence a suit to enforce the statute itself. The absence of a private right to enforce the statutory ceiling price obligations would be rendered meaningless if 340B entities could overcome that obstacle by suing to enforce the contract's ceiling price obligations instead. The statutory and contractual obligations, in short, are one and the same. See Grochowski v. Phoenix Construction, 318 F.3d 80, 86 (C.A.2 2003) (when a government contract confirms a statutory obligation, "a third-party private contract action [to enforce that obligation] would be inconsistent with ... the legislative scheme ... to the same extent as would a cause of action directly under the statute" (internal quotation marks omitted)).
Telling in this regard, the County based its suit on allegations that the manufacturers charged more than the § 340B ceiling price, see, e.g., Third Amended Complaint in No. 3:05–cv–03740 (ND Cal.), ¶ 1, 65, not that they violated any independent substantive obligation arising only from the PPAs. Repeatedly, the County acknowledged that § 340B is the source of the contractual term allegedly breached. See, e.g., id ., ¶ 28 ("[Section] 340B requires pharmaceutical manufacturers to ensure that § 340B Participants pay no more than the ‘ceiling price’ ... for any pharmaceutical product."); id ., ¶ 36 ("Under both § 340B and the PPA, [drug manufacturers] are required to ensure that the § 340B Participants ... pay no more for any product than the § 340B ceiling price.").
Whether a contracting agency may authorize third-party suits to enforce a Government contract is not at issue in this case. Cf. Brief for United States as Amicus Curiae 22. We can infer no such authorization where a contract simply incorporates statutorily required terms and otherwise fails to demonstrate any intent to allow beneficiaries to en-force those terms. Permitting such a suit, it is evident, would "allo[w] third parties to circumvent Congress's decision not to permit private enforcement of the statute." Id., at 23–24; cf. Brief for United States as Amicus Curiae in No. 09–15216(CA9), p. 21 ("In drafting and entering into [PPAs], HHS never imagined that a 340B entity could bring a third-party beneficiary lawsuit like [the County]'s.").
The Ninth Circuit determined that "[p]ermitting covered entities to sue as intended beneficiaries of the PPA is ... wholly compatible with the Section 340B program's objectives" to ensure "that drug companies comply with their obligations under the program and provide [the required] discounts." 588 F.3d, at 1251. Suits like the County's, the Court of Appeals reasoned, would spread the enforcement burden instead of placing it "[entirely] on the government." Ibid . (citing Price
v. Pierce, 823 F.2d 1114, 1121 (C.A.7 1987) ). But spreading the enforcement burden, the United States stressed, both in the Ninth Circuit and in this Court, is hardly what Congress contemplated when it "centralized enforcement in the government." Brief for United States as Amicus Curiae 32; see Brief for United States as Amicus Curiae in No. 09–15216(CA9), p. 13 (County's challenge is at odds with Congress' unitary administrative and enforcement scheme).
The County notes that in In re Pharmaceutical Industry Average Wholesale Price Litigation, 263 F.Supp.2d 172 (Mass.2003), the United States urged that the statute establishing the Medicaid Drug Rebate Program, § 1396r–8, does not preempt States from maintaining state-law fraud claims based on fraudulent reporting of "best prices" to HHS. Brief for Respondent 22–23. See Brief for United States as Amicus Curiae in No. 1:01–cv–12257 (D Mass.), pp. 6–9 (observing that States make their own payments to manufacturers and have long played a role in identifying and prosecuting Medicaid fraud). We take no position on this issue.
Congress made HHS administrator of both the Medicaid Drug Rebate Program and the 340B Program, the United States observed, Brief for United States as Amicus Curiae 33–34, and "[t]he interdependent nature of the two programs' requirements means that an adjudication of rights under one program must proceed with an eye towards any implications for the other," id ., at 34. Far from assisting HHS, suits by 340B entities would undermine the agency's efforts to administer both Medicaid and § 340B harmoniously and on a uniform, nationwide basis. Recognizing the County's right to proceed in court could spawn a multitude of dispersed and uncoordinated lawsuits by 340B entities. With HHS unable to hold the control rein, the risk of conflicting adjudications would be substantial.As earlier noted, see supra, at 1346, the Medicaid Rebate Program's statute prohibits HHS from disclosing pricing information in a form that could reveal the prices a manufacturer charges for drugs it produces. § 1396r–8(b)(3)(D). This ban on disclosure is a further indication of the incompatibility of private suits with the statute Congress enacted. If Congress meant to leave open the prospect of third-party beneficiary suits by 340B entities, it likely would not have barred the potential suitors from obtaining the very information necessary to determine whether their asserted rights have been violated.
Because the Ninth Circuit focused on the 340B Program in isolation, it failed to recognize that the interests of States under the Medicaid Drug Rebate Program and covered entities under the 340B Program may conflict. For example, "average" prices are used both to set the amount manufacturers must pay in Medicaid rebates and to establish § 340B ceiling prices. § 1396r–8(c) ; § 256b(a)(1). Typically, the lower the "average" price, the lower a product's price to a 340B entity. Brief for United States as Amicus Curiae in No. 09–15216, p. 31. But the higher the "average" price, the more a State Medicaid agency typically receives in rebates from the manufacturers. Ibid. HHS can use its expertise to ascertain and balance the competing interests. Id., at 31–32. Courts as first-line decisionmakers are not similarly equipped to deal with the whole picture.
HHS interprets this provision, the United States informs us, as prohibiting the agency from disclosing to covered entities the ceiling prices calculated based on information submitted by the manufacturers. Brief for United States as Amicus Curiae 28.
Going forward, the 2010 Patient Protection and Affordable Care Act, Pub.L. 111–148, 124 Stat. 119, in conjunction with the new administrative adjudication process directed by the Act, will require HHS to give covered entities access to some of the information submitted by manufacturers. Id., at 826, 42 U.S.C.A. § 256b(d)(3)(B)(iii).
It is true, as the Ninth Circuit observed, that HHS's Office of the Inspector General (OIG) has published reports finding that "HRSA lacks the oversight mechanisms and authority to ensure that [covered] entities pay at or below the ... ceiling price." 588 F.3d, at 1242 (quoting OIG, D. Levinson, Deficiencies in the Oversight of the 340B Drug Pricing Program ii (OEI–05–02–00072, Oct. 2005)). See also 588 F.3d, at 1242–1243 (citing OIG, D. Levinson, Review of 340B Prices 11 (OEI–05–02–00073, July 2006) (estimating that covered entities overpaid $3.9 million in June 2005 alone)). But Congress did not respond to the reports of inadequate HRSA enforcement by inviting 340B entities to launch lawsuits in district courts across the country. Instead, in the PPACA, Congress directed HRSA to create a formal dispute resolution procedure, institute refund and civil penalty systems, and perform audits of manufacturers. 124 Stat. 823–827, 42 U.S.C.A. § 256b(d). Congress thus opted to strengthen and formalize HRSA's enforcement authority, to make the new adjudicative framework the proper remedy for covered entities complaining of "overcharges and other violations of the discounted pricing requirements," id ., at 823, 42 U.S.C.A. § 256b(d)(1)(A), and to render the agency's resolution of covered entities' complaints binding, subject to judicial review under the APA, id ., at 827, 42 U.S.C.A. § 256b(d) (3)(C).
* * *
For the reasons stated, the judgment of the U.S. Court of Appeals for the Ninth Circuit is
Justice KAGAN took no part in the consideration or decision of this case.